<DOC>
	<DOCNO>NCT02874989</DOCNO>
	<brief_summary>The purpose study determine whether dasatinib quercetin reduce expression pro-inflammatory cell obtain skin biopsy .</brief_summary>
	<brief_title>Targeting Pro-Inflammatory Cells Idiopathic Pulmonary Fibrosis : Human Trial</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Quercetin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Men age 50 , time signing informed consent . 2 . Postmenopausal woman age 50 , time signing informed consent . Note : Postmenopausal define 12 month spontaneous amenorrhea determine selfreport . 3 . A clinical diagnosis IPF characteristic chest HRCT scan ( determined panel pulmonary radiologist ) OR biopsy show usual interstitial pneumonia ( UIP ) . 4 . Body Mass Index ( BMI ) within range 19 35 kg/ m2 ( inclusive ) , BMI = ( weight kg ) / ( height meter ) 2 . 5 . Subjects participate exercise program must willing maintain current activity level duration study period . 6 . Patients stable therapy nintedanib ( Ofev ) pirfenidone ( Esbriet ) past 3 months.ORPatients take nintedanib ( Ofev ) pirfenidone ( Esbriet ) may enrol previously tolerate one medication medication yet prescribe used patient . 7 . Giving sign informed consent . 8 . No plan travel next 6 week . 1 . More two moderate/severe IPF exacerbation within past year Exacerbation define worsen two follow major symptom : dyspnea , sputum volume , sputum purulence OR worsen one major symptom together least one follow additional symptom : sore throat , cold ( nasal discharge and/or nasal congestion ) , fever &gt; 37.5 Â° C without explain cause , increase cough , increase wheeze . A moderate exacerbation define event associate new prescription antibiotic and/or oral steroid . A severe exacerbation define event associate hospitalization emergency room visit . 2 . Any moderate/severe IPF exacerbation within past 4 week . 3 . History lung transplant . 4 . Use antiarrhythmic medication know cause QTc prolongation . 5 . Pulmonary hypertension cor pulmonale confirm echocardiography heart catheterization . 6 . Myocardial infarction , angina , hospitalization cardiac aetiology , stroke transient ischemic attack past 6 month . 7 . Chronic heart failure . 8 . Neurologic , musculoskeletal , condition opinion study physician limit subject 's ability complete study physical assessment . 9 . Uncontrolled diabetes ( HbA1c &gt; 7.5 % current use insulin ) . 10 . Subjects value outside specify range follow Key Clinical Laboratory Tests must exclude study : Renal function : Glomerular Filtration Rate ( GFR ) &lt; 30 ( mL/min/1.73 m2 ) use formula provide Study Reference Manual ( SRM ) . Note : Subjects receive dialysis exclude study . ALT &gt; 2xULN bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 11 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 12 . QTcB QTcF &gt; 450 msec QTc &gt; 480 msec subject Bundle Branch Block base single ECG . 13 . Subjects history malignancy complete remission least 2 year 1 year nonmelanoma skin carcinoma . 14 . The subject participate clinical trial receive investigational product within following time period prior participation current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 15 . History drug alcohol abuse within 5 year prior randomization . 16 . Use Coumadin antiplatelet anticoagulant medication . The use aspirin permit . 17 . Current use quinolone antibiotic . 18 . Low CBC . 19 . Cognitive Impairment ( MoCA score less 21 ) 20 . Other medical behavioral factor judgment principal investigator may interfere study participation ability follow intervention</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>